Plan the development programme
Prioritise indications, sequence studies and define the evidence, regulatory, operating and capital plan around an asset.
Clinical research consulting
TrialKey provides AI-enabled clinical research consulting for pharmaceutical, biotechnology and medtech sponsors. Combine clinical-development expertise, historical evidence and predictive modelling to decide what to develop, how to study it and how to manage the risks that matter.
Sponsor-side support from asset strategy through live study oversight
Consulting pathway
Decision-ready output: an evidence-grounded recommendation, supported alternatives and a practical action plan.
Why teams seek support
Clinical research consulting is rarely one isolated task. Most teams need a connected answer across strategy, protocol design, feasibility and execution.
Prioritise indications, sequence studies and define the evidence, regulatory, operating and capital plan around an asset.
Develop a study concept, write the synopsis and protocol, or pressure-test eligibility criteria, endpoints, sample size, visit burden, duration and feasibility.
Benchmark a proposed study against historical evidence, identify material risks and compare better-supported alternatives.
Select countries, sites, CROs and partners, then monitor recruitment, quality, cost, timelines and emerging delivery risk.
Connected capabilities
Start with the business or clinical decision—not a predefined report. TrialKey brings together the capabilities required to answer it.
Practical research support
Some engagements require a strategic answer. Others need experienced hands to turn that answer into the clinical research documents and submissions that move the study forward.
Turn the development concept and evidence into a clear synopsis covering objectives, population, treatment, endpoints, assessments and analysis assumptions.
Develop a new clinical trial protocol or strengthen an existing draft so the scientific rationale, design choices and operating requirements are coherent.
Prepare and coordinate ethics submission packages, responses and supporting materials for the relevant human research ethics committee or institutional review board.
Draft or review participant information sheets, informed consent forms and study-facing materials for clarity, consistency and submission readiness.
Assess the implications of requested changes, update affected study documents and support responses to ethics, regulatory or stakeholder questions.
Structure the document plan, responsibilities, review pathway and submission sequence needed to move from study concept toward activation.
Need a combination of clinical development consulting, protocol writing and ethics submission support? TrialKey can define one integrated work plan around the study and sponsor responsibilities.
Discuss the scopeThe TrialKey model
TrialKey's consulting model combines a larger evidence base and more systematic scenario analysis with the clinical judgement needed to turn results into a practical decision.
AI and modelling
Human expertise
570,000+
Clinical trials analysed
100,000+
Simulations per assessment
1,500+
Variables curated per trial
Consulting outputs
The output is shaped around the decision and its audience—from a focused study-team recommendation to an integrated development plan or board-ready investment paper.
A clear definition of the decision, assumptions and constraints
A focused evidence review using relevant clinical-trial precedents
Modelled scenarios, alternatives and material risk drivers
Expert interpretation of what the evidence means for the programme
A prioritised recommendation with actions, owners and decision points
Board, investment-committee or study-team-ready decision material
Questions
A clinical research consultant helps sponsors make scientific, statistical, operational and governance decisions across the clinical-development pathway. Depending on the question, this can include development strategy, study design, protocol development, feasibility, country and site selection, competitive analysis, CRO selection or study oversight.
TrialKey combines experienced clinical-development and operations input with structured historical trial evidence, machine learning, simulation and AI-assisted analysis. The technology expands and tests the available options; subject-matter experts interpret the results and remain responsible for the recommendation.
Yes. An engagement can begin with an asset, indication and treatment type, a development concept, a draft study plan, a synopsis or an existing protocol. The starting material determines which questions and evidence sources are prioritised.
No. TrialKey can complement specialist regulatory advisers, statisticians, medical writers and CRO delivery teams. It provides integrated decision support and, where required, an independent sponsor-side view of evidence, assumptions, options and execution risk.
Yes. TrialKey can support study synopsis and clinical trial protocol writing, protocol amendments, participant information and informed consent materials, and preparation or coordination of ethics, HREC and IRB submission packages. The exact scope is agreed for the study, jurisdiction and responsible sponsor team.
The service is designed for pharmaceutical, biotechnology and medtech sponsors, clinical-development teams, boards, investors and CRO partners making decisions about an asset, study or live programme.
Start with the decision
Bring us the asset, study or programme decision you need to make. We will show how TrialKey can structure the evidence, test the alternatives and define the first useful deliverable.